Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSP-1502 in Cystic Fibrosis with Pseudomonas Aeruginosa Infection
NCT06016088Phase 2Completed
- Sponsor
- Respirion Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of tobramycin + sodium calcium edetate in cystic fibrosis (CF), Pseudomonas aeruginosa infection, sponsored by Respirion Pharmaceuticals. Started Apr 2024; status: completed.
02
Drugs
tobramycin + sodium calcium edetate
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT06016088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06016088.